<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="509">
  <stage>Registered</stage>
  <submitdate>8/12/2004</submitdate>
  <approvaldate>8/12/2004</approvaldate>
  <nctid>NCT00098995</nctid>
  <trial_identification>
    <studytitle>Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer</studytitle>
    <scientifictitle>A Phase I Study Of Tirapazamine In Combination With Radiation And Weekly Cisplatin In Patients With Locally Advanced Cervical Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CDR0000393978</secondaryid>
    <secondaryid>PMCC-2004/354</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cervical Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - cisplatin
Treatment: drugs - tirapazamine
Treatment: other - brachytherapy
Treatment: other - radiation therapy

Treatment: drugs: cisplatin


Treatment: drugs: tirapazamine


Treatment: other: brachytherapy


Treatment: other: radiation therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum tolerated dose of tirapazamine</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety and tolerability</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Failure-free survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of failure for the site of first failure (local-regional, distant, or both)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete response rate at 12 weeks following study completion</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hypoxia by 18F-azomycinarabinoside (FAZA) PET scan at baseline and 12 wks following completion of radiotherapy correlated w/ obj. tumor response by PET- fludeoxyglucose F 18 (FDG) and local-regional failure</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed squamous cell carcinoma, adenocarcinoma, or
             adenosquamous cell carcinoma of the cervix

               -  Stage IB, IIA, IIB, III, or IVA disease

          -  No evidence of involvement of para-aortic nodes by CT scan, MRI, fluorodeoxyglucose
             positron emission tomography, or lymphadenectomy

               -  Involvement of common iliac nodes allowed

          -  No evidence of distant metastases

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  More than 6 months

        Hematopoietic

          -  Absolute neutrophil count = 1,500/mm^3

          -  Platelet count = 100,000/mm^3

        Hepatic

          -  Bilirubin &lt; 1.25 times upper limit of normal (ULN)

          -  AST and ALT = 3 times ULN

        Renal

          -  Calculated creatinine clearance = 60 mL/min OR

          -  Glomerular filtration rate = 60 mL/min

        Cardiovascular

          -  No significant cardiac disease that would preclude IV fluid load required for
             administration of cisplatin

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

        Other

          -  No symptomatic peripheral neuropathy = grade 2

          -  No clinically significant sensori-neural hearing impairment interfering with
             activities of daily living or requiring a hearing aid

               -  Audiometric changes alone of any severity allowed

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biological composition to tirapazamine or cisplatin

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other concurrent uncontrolled illness

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent epoetin alfa

          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)

          -  No concurrent pegfilgrastim

        Chemotherapy

          -  No prior chemotherapy for another malignancy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior pelvic or abdominal radiotherapy for another malignancy

          -  No prior radiotherapy to = 15% of bone marrow-bearing areas

          -  No concurrent intensity-modulated radiotherapy

          -  No concurrent interstitial brachytherapy

        Surgery

          -  Not specified

        Other

          -  No prior treatment for invasive cervical cancer

          -  No other concurrent therapeutic investigational agents

          -  No other concurrent anticancer therapy

          -  No concurrent systemic retinoids

          -  No concurrent amifostine

          -  No concurrent combination antiretroviral therapy for HIV-positive patients</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>22</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <postcode>8006 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy, such as tirapazamine and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Tirapazamine may help cisplatin kill more tumor cells by making tumor cells more
      sensitive to the drug. Radiation therapy uses high-energy x-rays to kill tumor cells.
      Tirapazamine may also make tumor cells more sensitive to radiation therapy. Giving radiation
      therapy in different ways together with combination chemotherapy may kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of tirapazamine when
      given together with cisplatin and radiation therapy in treating patients with stage IB, stage
      II, stage III, or stage IVA cervical cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00098995</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Danny Rischin, MD</name>
      <address>Peter MacCallum Cancer Centre, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>